Results 41 to 50 of about 1,261,156 (366)

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis

SAGE Open Medicine, 2020
Objectives: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system ...
Kiyoka Matsumoto, Shiori Hasegawa, Satoshi Nakao, Kazuyo Shimada, Ririka Mukai, Mizuki Tanaka, Riko Satake, Yu Yoshida, Fumiya Goto, Misaki Inoue, Hiroaki Ikesue, Kazuhiro Iguchi, Tohru Hashida, Mitsuhiro Nakamura   +13 more
doaj   +1 more source

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System [PDF]

Drugs - Real World Outcomes, 2019
Serious cardiovascular adverse events (SCAEs) associated with intravenous sedatives remain poorly characterized.The objective of this study was to compare SCAE incidence, types, and mortality between intravenous benzodiazepines (i.e., diazepam, lorazepam, and midazolam), dexmedetomidine, and propofol in the USA over 8 years regardless of the clinical ...
Jonathan Weinstock, Mo Dimbil, Nick O'Donnell, Christopher Madias, Keith B. Hoffman, Matthew S. Duprey, Nada S. Al-Qadheeb, John W. Devlin, John W. Devlin   +8 more
openaire   +3 more sources

Methods for Detecting and Measuring Adverse Hospital Events [PDF]

Iranian Journal of Public Health, 2005
Introduction: An adverse event is defined as an unexpected event such as a patient fall, a drug reaction or an infection, which leads to patient injury and is caused by healthcare management rather than patient own diseases.
A Baba-Akbari Sari, TA Sheldon
doaj   +2 more sources

Spillover and crossover effects of exposure to work‐related aggression and adversities: A dyadic diary study

Aggressive Behavior, Volume 49, Issue 1, Page 85-95, January 2023., 2023
Abstract The past two decades have produced extensive evidence on the manifold and severe outcomes for victims of aggression exposure in the workplace. However, due to the dominating individual‐centered approach, most findings miss a social network perspective.
Alexander Herrmann, Jürgen Glaser, Tobias Greitemeyer   +2 more
wiley   +1 more source

Evaluation of patient doses for routine digital radiography procedures toward establishing an institutional diagnostic reference levels: A case study in Sri Lanka

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract The present study was conducted as part of a comprehensive work to establish National Diagnostic Reference Levels (NDRLs) in Sri Lanka for the first time. DRLs can be used as an effective optimization tool for identifying unusually high or low patient doses during X‐ray examinations.
Sachith Welarathna, Sivakumar Velautham, Mihira Wanninayake, Sivananthan Sarasanandarajah   +3 more
wiley   +1 more source

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Apalutamide is a new drug class, which is approved to treat prostate cancer (PCa). The aim of our study was to assess the safety profiles of apalutamide in real-world through data mining of the United States Food and Drug Administration ...
Zhihong Fang, Zhiqiang Xu, Wei Zhu, Mingming Yu, Chunmei Ji   +4 more
doaj   +1 more source

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Journal of Clinical Medicine, 2021
Background: Cardiovascular safety concerns for major cardiovascular events (MACE) were raised during the clinical trials of romosozumab. We aimed to evaluate the cardiovascular safety profile of romosozumab in a large pharmacovigilance database. Methods:
Annika Vestergaard Kvist, Junaid Faruque, E. Vallejo-Yagüe, S. Weiler, E. Winter, A. M. Burden   +5 more
semanticscholar   +1 more source

Adverse drug event reporting systems: a systematic review [PDF]

British Journal of Clinical Pharmacology, 2016
AimAdverse drug events (ADEs) are harmful and unintended consequences of medications. Their reporting is essential for drug safety monitoring and research, but it has not been standardized internationally. Our aim was to synthesize information about the type and variety of data collected within ADE reporting systems.MethodsWe developed a systematic ...
David Peddie, David Peddie, Maeve E. Wickham, Maeve E. Wickham, Ellen Balka, Ellen Balka, Mary M. Doyle-Waters, Katherin Badke, Katherin Badke, Chantelle Bailey, Chantelle Bailey, Corinne M. Hohl, Corinne M. Hohl, Serena S Small, Serena S Small   +14 more
openaire   +2 more sources

A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab

Expert Opinion on Drug Safety, 2022
Romosozumab is a novel drug for the treatment of osteoporosis. The adverse reactions of romosozumab still need to be explored. The FDA Adverse Event Reporting System (FAERS) provides an enormous dataset for adverse events (AEs) analysis. AEs registered in FAERS between January 2019 and December 2020 were collected for this study.
Zepeng Chen, Ming Li, Shuzhen Li, Yuxi Li, Junyan Wu, Kaifeng Qiu, Xiaoxia Yu, Lin Huang, Guanghui Chen   +8 more
openaire   +2 more sources

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System

Frontiers in Pharmacology, 2022
Background: Due to the embryotoxicity found in animal studies and scarce clinical data in pregnant women, it is still controversial whether entecavir (ETV) and adefovir dipivoxil (ADV) are safe during human pregnancy. This is of paramount importance when
Renjun Yang, Nuoya Yin, Ying Zhao, Dandan Li, Xuanling Zhang, Xingang Li, Yang-Yang Zhang, F. Faiola   +7 more
semanticscholar   +1 more source